B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

Robéria Mendonça de Pontes, Juan Flores-Montero, EuroFlow Consortium, Luzalba Sanoja-Flores, Noemi Puig, Roberto J. Pessoa de Magalhães, Alba Corral-Mateos, Anna Beatriz Salgado, Omar García-Sánchez, José Pérez-Morán, Maria Victoria Mateos, Leire Burgos, Bruno Paiva, Jeroen Te Marvelde, Vincent H.J. van der Velden, Carlos Aguilar, Abelardo Bárez, Aranzazú García-Mateo, Jorge Labrador, Pilar LeozCarmen Aguilera-Sanz, Brian Durie, Jacques J.M. van Dongen*, Angelo Maiolino, Elaine Sobral da Costa, Alberto Orfao

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)
4 Downloads (Pure)

Abstract

B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19 nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.

Original languageEnglish
Article number1704
JournalCancers
Volume13
Issue number7
DOIs
Publication statusPublished - 3 Apr 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Fingerprint

Dive into the research topics of 'B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients'. Together they form a unique fingerprint.

Cite this